Determining the binding affinity of therapeutic monoclonal antibodies towards their native unpurified antigens in human serum.

Monoclonal antibodies (mAbs) are a growing segment of therapeutics, yet their in vitro characterization remains challenging. While it is essential that a therapeutic mAb recognizes the native, physiologically occurring epitope, the generation and selection of mAbs often rely on the use of purified r...

Full description

Bibliographic Details
Main Authors: Christine Bee, Yasmina N Abdiche, Jaume Pons, Arvind Rajpal
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3819287?pdf=render
id doaj-9c7e62bb0dfa40fc8e96611fd66a3297
record_format Article
spelling doaj-9c7e62bb0dfa40fc8e96611fd66a32972020-11-25T01:42:24ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-01811e8050110.1371/journal.pone.0080501Determining the binding affinity of therapeutic monoclonal antibodies towards their native unpurified antigens in human serum.Christine BeeYasmina N AbdicheJaume PonsArvind RajpalMonoclonal antibodies (mAbs) are a growing segment of therapeutics, yet their in vitro characterization remains challenging. While it is essential that a therapeutic mAb recognizes the native, physiologically occurring epitope, the generation and selection of mAbs often rely on the use of purified recombinant versions of the antigen that may display non-native epitopes. Here, we present a method to measure both, the binding affinity of a therapeutic mAb towards its native unpurified antigen in human serum, and the antigen's endogenous concentration, by combining the kinetic exclusion assay and Biacore's calibration free concentration analysis. To illustrate the broad utility of our method, we studied a panel of mAbs raised against three disparate soluble antigens that are abundant in the serum of healthy donors: proprotein convertase subtilisin/kexin type 9 (PCSK9), progranulin (PGRN), and fatty acid binding protein (FABP4). We also determined the affinity of each mAb towards its purified recombinant antigen and assessed whether the interactions were pH-dependent. Of the six mAbs studied, three did not appear to discriminate between the serum and recombinant forms of the antigen; one mAb bound serum antigen with a higher affinity than recombinant antigen; and two mAbs displayed a different affinity for serum antigen that could be explained by a pH-dependent interaction. Our results highlight the importance of taking pH into account when measuring the affinities of mAbs towards their serum antigens, since the pH of serum samples becomes increasingly alkaline upon aerobic handling.http://europepmc.org/articles/PMC3819287?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Christine Bee
Yasmina N Abdiche
Jaume Pons
Arvind Rajpal
spellingShingle Christine Bee
Yasmina N Abdiche
Jaume Pons
Arvind Rajpal
Determining the binding affinity of therapeutic monoclonal antibodies towards their native unpurified antigens in human serum.
PLoS ONE
author_facet Christine Bee
Yasmina N Abdiche
Jaume Pons
Arvind Rajpal
author_sort Christine Bee
title Determining the binding affinity of therapeutic monoclonal antibodies towards their native unpurified antigens in human serum.
title_short Determining the binding affinity of therapeutic monoclonal antibodies towards their native unpurified antigens in human serum.
title_full Determining the binding affinity of therapeutic monoclonal antibodies towards their native unpurified antigens in human serum.
title_fullStr Determining the binding affinity of therapeutic monoclonal antibodies towards their native unpurified antigens in human serum.
title_full_unstemmed Determining the binding affinity of therapeutic monoclonal antibodies towards their native unpurified antigens in human serum.
title_sort determining the binding affinity of therapeutic monoclonal antibodies towards their native unpurified antigens in human serum.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2013-01-01
description Monoclonal antibodies (mAbs) are a growing segment of therapeutics, yet their in vitro characterization remains challenging. While it is essential that a therapeutic mAb recognizes the native, physiologically occurring epitope, the generation and selection of mAbs often rely on the use of purified recombinant versions of the antigen that may display non-native epitopes. Here, we present a method to measure both, the binding affinity of a therapeutic mAb towards its native unpurified antigen in human serum, and the antigen's endogenous concentration, by combining the kinetic exclusion assay and Biacore's calibration free concentration analysis. To illustrate the broad utility of our method, we studied a panel of mAbs raised against three disparate soluble antigens that are abundant in the serum of healthy donors: proprotein convertase subtilisin/kexin type 9 (PCSK9), progranulin (PGRN), and fatty acid binding protein (FABP4). We also determined the affinity of each mAb towards its purified recombinant antigen and assessed whether the interactions were pH-dependent. Of the six mAbs studied, three did not appear to discriminate between the serum and recombinant forms of the antigen; one mAb bound serum antigen with a higher affinity than recombinant antigen; and two mAbs displayed a different affinity for serum antigen that could be explained by a pH-dependent interaction. Our results highlight the importance of taking pH into account when measuring the affinities of mAbs towards their serum antigens, since the pH of serum samples becomes increasingly alkaline upon aerobic handling.
url http://europepmc.org/articles/PMC3819287?pdf=render
work_keys_str_mv AT christinebee determiningthebindingaffinityoftherapeuticmonoclonalantibodiestowardstheirnativeunpurifiedantigensinhumanserum
AT yasminanabdiche determiningthebindingaffinityoftherapeuticmonoclonalantibodiestowardstheirnativeunpurifiedantigensinhumanserum
AT jaumepons determiningthebindingaffinityoftherapeuticmonoclonalantibodiestowardstheirnativeunpurifiedantigensinhumanserum
AT arvindrajpal determiningthebindingaffinityoftherapeuticmonoclonalantibodiestowardstheirnativeunpurifiedantigensinhumanserum
_version_ 1725036655492988928